News | Nuclear Imaging | December 26, 2019

Dr. Thomas Chaly pushes for approval of imaging agent to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s


December 26, 2019 — The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) approval for a new positron emission tomography (PET) drug to combat Parkinson’s disease. Fluorodopa F-18 (FDOPA) Injection (NDA 200655) will help visualize dopaminergic nerve terminals in the striatum for the evaluation of patients with suspected Parkinsonian syndromes.

Thomas Chaly, Ph.D., chief of cyclotron/radiochemistry at the Feinstein Institutes, was instrumental in getting this FDA approval. “This FDA approval is the pinnacle of our venture to have a safe and effective imaging agent for the differential diagnosis of Parkinsonian Syndromes,” said Chaly, who is also an associate investigator in the Institute of Molecular Medicine.

A PET scan is an imaging test that helps to understand the disease condition of the organs at the cellular level. PET uses a short-lived radiopharmaceutical to visually observe the affected area of the organ. In patients with Parkinson’s disease who experience loss of dopaminergic neurons, FDOPA uptake will be lower and this reduced uptake can be visually observed in the PET scan.

Fluorodopa F-18 Injection Helps Visualize Dopaminergic Nerve Terminals

Fluorodopa PET can be used to follow the disease’s progression. In addition, in patients with Parkinson’s disease who have received intracerebral transplantation of adrenal medulla tissue or fetal mesencephalic tissue, FDOPA PET may help to study the integrity and activity of the implant.

“With this approval, PET centers across the United States can incorporate FDOPA F-18 into their diagnostic and treatment follow up programs for patients with Parkinson’s disease,” Chaly said.   

David Eidelberg, M.D., and Vijay Dhawan, Ph.D., helped direct the clinical studies for this NDA approval.

Fluorodopa F-18 Injection is injected into a vein in preparation for a PET scan to help detect the damaged or lost dopaminergic nerve cells. It is to be used in addition to other tests for diagnosing Parkinsonian syndromes. 

To learn more about Fluorodopa F-18 trial. 

 

Related Content:

PET Aids Dopamine Cell Transplantation for Parkinson’s Patients

Trends in Molecular Imaging

Radiopharmaceutical Product Receives Positive Opinion in Europe

Related Content

News | Proton Therapy

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology ...

Time July 01, 2022
arrow
News | Radiology Business

June 29, 2022 — Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed ...

Time June 29, 2022
arrow
News | Contrast Media

June 23, 2022 — Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol ...

Time June 23, 2022
arrow
News | SNMMI

June 22, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13 ...

Time June 22, 2022
arrow
News | SNMMI

June 22, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear ...

Time June 22, 2022
arrow
News | PET Imaging

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as ...

Time June 21, 2022
arrow
News | SNMMI

June 21, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the ...

Time June 20, 2022
arrow
News | SNMMI

June 16, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at ...

Time June 16, 2022
arrow
News | SPECT Imaging

June 15, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems ...

Time June 15, 2022
arrow
News | PET Imaging

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Time June 15, 2022
arrow
Subscribe Now